Shares of ADMA Biologics Inc (NASDAQ:ADMA) have been given a consensus broker rating score of 1.33 (Strong Buy) from the three analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and two have given a strong buy rating to the company. ADMA Biologics’ rating score has improved by 20.4% in the last three months as a result of a number of analysts’ ratings changes.

Analysts have set a 1-year consensus price objective of $7.63 for the company and are expecting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also given ADMA Biologics an industry rank of 161 out of 265 based on the ratings given to its competitors.

ADMA has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating and issued a $8.00 price objective (down from $13.00) on shares of ADMA Biologics in a research note on Monday, December 11th. Raymond James Financial upgraded shares of ADMA Biologics from a “market perform” rating to an “outperform” rating and set a $5.00 target price for the company in a research report on Tuesday, November 14th.

In related news, insider Adam S. Grossman bought 485,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The stock was purchased at an average price of $2.15 per share, for a total transaction of $1,042,750.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Eric I. Richman bought 25,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were bought at an average price of $2.15 per share, with a total value of $53,750.00. Following the transaction, the director now owns 31,300 shares of the company’s stock, valued at approximately $67,295. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 526,500 shares of company stock valued at $1,131,975. 60.44% of the stock is owned by company insiders.

An institutional investor recently raised its position in ADMA Biologics stock. Iguana Healthcare Management LLC increased its stake in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 276.7% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 565,000 shares of the biotechnology company’s stock after acquiring an additional 415,000 shares during the quarter. Iguana Healthcare Management LLC owned about 2.19% of ADMA Biologics worth $1,740,000 at the end of the most recent quarter. Institutional investors own 32.78% of the company’s stock.

Shares of ADMA Biologics (ADMA) traded down $0.12 during midday trading on Friday, hitting $3.57. 199,337 shares of the stock were exchanged, compared to its average volume of 142,019. The company has a current ratio of 2.36, a quick ratio of 1.35 and a debt-to-equity ratio of 2.26. The stock has a market capitalization of $95.18, a PE ratio of -4.35 and a beta of 2.50. ADMA Biologics has a 1 year low of $2.01 and a 1 year high of $5.74.

ILLEGAL ACTIVITY WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at

ADMA Biologics Company Profile

ADMA Biologics, Inc is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and commercialization of human plasma and plasma-derived therapeutics.

Get a free copy of the Zacks research report on ADMA Biologics (ADMA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with's FREE daily email newsletter.